Figure 5. PRPF3 genomic alterations in HCC (cBioPortal). (A) OncoPrint of PRPF3 alterations in LIHC cohort. The different types of genetic alterations are highlighted in different colors. (B) PRPF3 expression in different PRPF3 CNV groups. PRPF3 amplification (AMP) group has a significantly higher expression level. (C) Distribution of PRPF3 CNV frequency in different stage and grade subgroups. The percentage number on the right of the bar indicates the ratio of patients with PRPF3 gain or AMP in all this subgroup patients. (D) To reduce the noise of disease irrelevant deaths, survival time that was greater than five years was truncated to five years. PRPF3 CNV affects overall survival and disease-free survival. ***, p < 0.001.